Navigation Links
Sight loss risk doubles in overweight people

Campaigners yesterday sent warnings that in Scotland, a million overweight adults face twice the risk of sight loss because of their weight.//

Awareness about the relationship between obesity and blindness has to be created among more people, according to a report by the Royal National Institute of the Blind (RNIB) Scotland.

The risk of developing Age-related Macular Degeneration (AMD) doubles when damage is caused to the body due to obesity. In the UK, AMD is the major cause of sight loss. The risk of developing diabetes increases 10 times in obese people.60% of these diabetic cases suffer from sight problems like cataract.

John Legg, director of RNIB Scotland, said: "Most people wrongly assume that if they don't have any obvious problems with their sight, that everything must be fine. With the huge increase in obesity that we have seen in recent years, many people are now jeopardizing their sight in later life."

According to Trish Richmond, 42, of Motherwell, obesity is the cause of her blindness. She has reduced to 17 stone from 20. She is suffering from glaucoma, diabetic retinopathy and cataracts. "In 1999 the doctors said there was nothing more they could do to save my sight," she said. "No-one ever said to me all this could be due to my weight. If they had I might have been more motivated to lose weight," she said.

By 2010, one in three Scots will be clinically obese, according to estimation.
GYT
'"/>




Page: 1

Related medicine news :

1. New Eye Surgery Gives Hope To Short-Sighted
2. Increased Risk Of Losing Sight In Obese People.
3. Gene Therapy May Help Restore Sight In Congenital blindness
4. Quality Of Dietary Carbohydrates May Determine Quality Of Eye Sight
5. Women Compensated For Losing Eye-Sight After Undergoing Cataract Operation
6. Glaucoma: Silently Stealing Sight from Millions
7. Bionic Eye may Restore Sight to the Blind
8. Six Lose Sight Due to Medical Negligence in Eye Camp
9. World’s First Attempt To Restore Sight Using Gene Therap
10. Breast cancer risk doubles by high sex hormone levels
11. Down syndrome life anticipation doubles
Post Your Comments:
Breaking Medicine Technology:China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 2China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 3China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 4China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 5China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 6China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 7China Yongxin Pharmaceuticals, Inc. Announces Results for the Third Quarter Ended September 30, 2009 8OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 2OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 3OrBIT Study Long Term Results Show Sustained Therapeutic Effect of Percutaneous Tibial Nerve Stimulation at 12 Months 4Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 2Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 3Arrayit Diagnostics Announces Sponsored Research Agreement With Wayne State University and Arrayit Corporation 4Medical Technology Executives Descend on D C as AdvaMed 2009 3A The MedTech Conference Kicks Off and Health Care Debate Continues 5384 1Medical Technology Executives Descend on D C as AdvaMed 2009 3A The MedTech Conference Kicks Off and Health Care Debate Continues 5384 2Medical Technology Executives Descend on D C as AdvaMed 2009 3A The MedTech Conference Kicks Off and Health Care Debate Continues 5384 3CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 1CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 2CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 3CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 4CSL Behring Announces FDA Approval of Berinert 28R 29 First and Only Therapy Approved for the Treatment of Acute Abdominal and Facial Attacks of Here 5379 5A Little Cash Buys a Lot of Calories at the Corner Store 59282 1A Little Cash Buys a Lot of Calories at the Corner Store 59282 2